Bruker Corp. Coverage Initiated at Cleveland Research (BRKR)
Analysts at Cleveland Research started coverage on shares of Bruker Corp. (NASDAQ:BRKR) in a research report issued to clients and investors on Friday, ARN reports. The firm set a “buy” rating on the stock.
A number of other analysts have also recently weighed in on BRKR. Analysts at Wells Fargo & Co. downgraded shares of Bruker Corp. (NASDAQ:BRKR) from an “outperform” rating to a “market perform” rating in a research note to investors on Friday. Separately, analysts at Mizuho raised their price target on shares of Bruker Corp. (NASDAQ:BRKR) from $21.00 to $25.00 in a research note to investors on Friday, August 23rd. They now have a “buy” rating on the stock. Finally, analysts at Merrill Lynch upgraded shares of Bruker Corp. (NASDAQ:BRKR) from an “underperform” rating to a “neutral” rating in a research note to investors on Thursday, August 22nd.
Five investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $22.23.
Bruker Corp. (NASDAQ:BRKR) opened at 20.72 on Friday. Bruker Corp. has a 1-year low of $11.58 and a 1-year high of $21.11. The stock’s 50-day moving average is $20.11 and its 200-day moving average is $18.16. The company has a market cap of $3.456 billion and a price-to-earnings ratio of 43.26.
Bruker Corp. (NASDAQ:BRKR) last issued its quarterly earnings data on Wednesday, July 31st. The company reported $0.18 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.04. The company had revenue of $454.90 million for the quarter, compared to the consensus estimate of $426.39 million. During the same quarter in the previous year, the company posted $0.12 earnings per share. The company’s revenue for the quarter was up 8.1% on a year-over-year basis. Analysts expect that Bruker Corp. will post $0.81 EPS for the current fiscal year.
Bruker Corporation (NASDAQ:BRKR) is a global manufacturer of scientific instruments that address the rapidly evolving needs of a diverse array of customers in life science, pharmaceutical, biotechnology, clinical and molecular diagnostics research, as well as in materials and chemical analysis in various industries and government applications.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.